Nautilus Biotechnology, Inc.

US$2.23As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:NAUTHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (22.39%)
Div yield —
ROE (41.01%)
Biotechnology
Beta (5Y) 0.66
PE TTM —
TSR TTM 67.67%
Mkt cap US$284.0M
ROIC (23.59%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$2.60
16.74%
(44.94%)
Hold 0|7|8|7|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.04
0.04
0.04
0.05
1.33%
1.09%
8.07%
21.55%
Revenue$M
27.18
28.57
28.36
29.83
3.67%
3.72%
4.61%
9.19%
Peers (US$284.0M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.643
(0.012)
(0.012)
EBIT/Intx
1.166
0.172
0.176
Own earn%
(52.13)
48.35
68.61
Sh yield%
36.38
17.02
21.53
Owners
Insiders/Inst%
9.24
34.84
Short interest%
4.12
SBC / revenue%
2.88
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
5
Op margin range%
9–14
$1 testx
0.9
Incr. ROIC%
21